Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women

Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women

OBJECTIVE: To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17beta-estradiol (17beta-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17beta-E2 and norethisterone acetate (NETA) regimens. STUDY DESIGN: This was a double-blind, randomized, mu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecological endocrinology 2005-09, Vol.21 (3), p.142
Hauptverfasser: Bouchard, P, F De Cicco-Nardone, Spielmann, D, Garcea, N
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 142
container_title Gynecological endocrinology
container_volume 21
creator Bouchard, P
F De Cicco-Nardone
Spielmann, D
Garcea, N
description OBJECTIVE: To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17beta-estradiol (17beta-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17beta-E2 and norethisterone acetate (NETA) regimens. STUDY DESIGN: This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17beta-E2/0.125 mg TMG, 2 mg 17beta-E2/1 mg NETA or 1 mg 17beta-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. RESULTS: The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17beta-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17beta-E2/0.125 mg TMG and the 1 mg 17beta-E2/0.5 mg NETA groups, but greater in the 2 mg 17beta-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. CONCLUSION: Continuous combined 1 mg 17beta-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17beta-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_197418681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>932337761</sourcerecordid><originalsourceid>FETCH-LOGICAL-g521-4dc99b9bb18ac513b08e7dc3e65daca56e2716c860aab07887c6f55b67191aa83</originalsourceid><addsrcrecordid>eNp1kN1KxDAQhYsouK6-Q_C-mGybn17q4h8I3uydyDJJpjVLm6xJqvh0vppZ9NarmWHmnPMxR9WCtbKpqRTiuFrQjrO64R09rc5S2lHKmlauFtX3zYhonR_IPobejUjAW4LehglzdDCSBD3mLxJ6YoLPzs9hTqWdtPNoScTBTegTYWQaCJMvGjO81phyBOvCeFVMJhzKHDySD4xpPtyGSFb_CHyImN9cyhgPEjBln5E4T_Yh5ZIV9jCnAvZZEP15ddLDmPDiry6rzd3tZv1QPz3fP66vn-qBr1jdWtN1utOaKTCcNZoqlNY0KLgFA1zgSjJhlKAAmkqlpBE951pI1jEA1Syry1_b8qX3ucBud2GOviRuWSdbpoRizQ-xd3WK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197418681</pqid></control><display><type>article</type><title>Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women</title><source>Taylor &amp; Francis Journals Complete</source><creator>Bouchard, P ; F De Cicco-Nardone ; Spielmann, D ; Garcea, N</creator><creatorcontrib>Bouchard, P ; F De Cicco-Nardone ; Spielmann, D ; Garcea, N</creatorcontrib><description>OBJECTIVE: To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17beta-estradiol (17beta-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17beta-E2 and norethisterone acetate (NETA) regimens. STUDY DESIGN: This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17beta-E2/0.125 mg TMG, 2 mg 17beta-E2/1 mg NETA or 1 mg 17beta-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. RESULTS: The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17beta-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17beta-E2/0.125 mg TMG and the 1 mg 17beta-E2/0.5 mg NETA groups, but greater in the 2 mg 17beta-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. CONCLUSION: Continuous combined 1 mg 17beta-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17beta-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>CODEN: GYENER</identifier><language>eng</language><publisher>Carnforth: Taylor &amp; Francis Ltd</publisher><ispartof>Gynecological endocrinology, 2005-09, Vol.21 (3), p.142</ispartof><rights>Copyright CRC Press Sep 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Bouchard, P</creatorcontrib><creatorcontrib>F De Cicco-Nardone</creatorcontrib><creatorcontrib>Spielmann, D</creatorcontrib><creatorcontrib>Garcea, N</creatorcontrib><title>Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women</title><title>Gynecological endocrinology</title><description>OBJECTIVE: To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17beta-estradiol (17beta-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17beta-E2 and norethisterone acetate (NETA) regimens. STUDY DESIGN: This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17beta-E2/0.125 mg TMG, 2 mg 17beta-E2/1 mg NETA or 1 mg 17beta-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. RESULTS: The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17beta-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17beta-E2/0.125 mg TMG and the 1 mg 17beta-E2/0.5 mg NETA groups, but greater in the 2 mg 17beta-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. CONCLUSION: Continuous combined 1 mg 17beta-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17beta-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.</description><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kN1KxDAQhYsouK6-Q_C-mGybn17q4h8I3uydyDJJpjVLm6xJqvh0vppZ9NarmWHmnPMxR9WCtbKpqRTiuFrQjrO64R09rc5S2lHKmlauFtX3zYhonR_IPobejUjAW4LehglzdDCSBD3mLxJ6YoLPzs9hTqWdtPNoScTBTegTYWQaCJMvGjO81phyBOvCeFVMJhzKHDySD4xpPtyGSFb_CHyImN9cyhgPEjBln5E4T_Yh5ZIV9jCnAvZZEP15ddLDmPDiry6rzd3tZv1QPz3fP66vn-qBr1jdWtN1utOaKTCcNZoqlNY0KLgFA1zgSjJhlKAAmkqlpBE951pI1jEA1Syry1_b8qX3ucBud2GOviRuWSdbpoRizQ-xd3WK</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Bouchard, P</creator><creator>F De Cicco-Nardone</creator><creator>Spielmann, D</creator><creator>Garcea, N</creator><general>Taylor &amp; Francis Ltd</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope></search><sort><creationdate>20050901</creationdate><title>Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women</title><author>Bouchard, P ; F De Cicco-Nardone ; Spielmann, D ; Garcea, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g521-4dc99b9bb18ac513b08e7dc3e65daca56e2716c860aab07887c6f55b67191aa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bouchard, P</creatorcontrib><creatorcontrib>F De Cicco-Nardone</creatorcontrib><creatorcontrib>Spielmann, D</creatorcontrib><creatorcontrib>Garcea, N</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bouchard, P</au><au>F De Cicco-Nardone</au><au>Spielmann, D</au><au>Garcea, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women</atitle><jtitle>Gynecological endocrinology</jtitle><date>2005-09-01</date><risdate>2005</risdate><volume>21</volume><issue>3</issue><spage>142</spage><pages>142-</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><coden>GYENER</coden><abstract>OBJECTIVE: To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17beta-estradiol (17beta-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17beta-E2 and norethisterone acetate (NETA) regimens. STUDY DESIGN: This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17beta-E2/0.125 mg TMG, 2 mg 17beta-E2/1 mg NETA or 1 mg 17beta-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. RESULTS: The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17beta-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17beta-E2/0.125 mg TMG and the 1 mg 17beta-E2/0.5 mg NETA groups, but greater in the 2 mg 17beta-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. CONCLUSION: Continuous combined 1 mg 17beta-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17beta-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.</abstract><cop>Carnforth</cop><pub>Taylor &amp; Francis Ltd</pub></addata></record>
fulltext fulltext
identifier ISSN: 0951-3590
ispartof Gynecological endocrinology, 2005-09, Vol.21 (3), p.142
issn 0951-3590
1473-0766
language eng
recordid cdi_proquest_journals_197418681
source Taylor & Francis Journals Complete
title Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17[beta]-estradiol/trimegestone versus 1 or 2 mg 17[beta]-estradiol/norethisterone acetate in postmenopausal women
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bleeding%20profile%20and%20endometrial%20safety%20of%20continuous%20combined%20regimens%201%20mg%2017%5Bbeta%5D-estradiol/trimegestone%20versus%201%20or%202%20mg%2017%5Bbeta%5D-estradiol/norethisterone%20acetate%20in%20postmenopausal%20women&rft.jtitle=Gynecological%20endocrinology&rft.au=Bouchard,%20P&rft.date=2005-09-01&rft.volume=21&rft.issue=3&rft.spage=142&rft.pages=142-&rft.issn=0951-3590&rft.eissn=1473-0766&rft.coden=GYENER&rft_id=info:doi/&rft_dat=%3Cproquest%3E932337761%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197418681&rft_id=info:pmid/&rfr_iscdi=true